Search Weight Loss Topics: |
Acerus Reports Third Quarter and Year-to-Date Fiscal 2019 Financial Results – Business Wire
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (Acerus or the Company) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three- and nine-month period ended September 30, 2019. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (IFRS).
Third Quarter Highlights
In anticipation of the closing of the A&R Agreement, we have begun the process of standing-up both a US market access team and specialty sales organization to co-promote NATESTO to the United States market. This expansion of our footprint to enter the United States market confirms our mens health strategy and truly establishes Acerus as a globally focused company headquartered in Canada, not just a company servicing the Canadian marketplace, said Ed Gudaitis, President and Chief Executive Officer of Acerus. We are also excited about the results of a clinical study showing that NATESTO increases serum testosterone and improves symptoms while maintaining normal semen parameters in men with low testosterone. This positive study, presented initially by Dr. Ranjith Ramasamy, MD, Associate Professor and Director of Reproductive Urology at the University of Miami School of Medicine, at the American Society for Reproductive Medicine Conference on October 17, 2019, and subsequently at an Acerus Key Opinion Leader presentation in New York City on October 30, 2019, clearly differentiates NATESTO from other approved testosterone therapies. We are very excited by the outcomes of this study and will look to further develop the growing evidence-base supporting NATESTO.
Summary of Results for the Three Months Ended September 30, 2019 (compared to the Three Months Ended September 30, 2018 unless otherwise noted)
Total revenue in the quarter was negative $0.2 million compared to $1.6 million in the third quarter of 2018. This decline is due to a $0.8 million drop in Estrace and UrivarxTM product revenues and the net impact of $0.6 million in Q3-2019 for returns associated with the delay in returning NATESTO to the Canadian and South Korean markets (previously it was assumed that the product would be replaced rather than returned) and reversing the Q2-2019 $0.1 million charge to revenue discounts for incentives to customers to accept replacement product.
On August 2, 2019, we announced that we would voluntarily replace certain NATESTO lots released in the Canadian and South Korean markets, which was expected to cause temporary shortages in those markets. We have identified four commercial lots of NATESTO released in the Canadian and South Korean markets that were found to be non-conforming during long-term stability studies, even though such lots were fully in-specification at the time of release. This post-release non-conformity is not harmful to the patient, but may result in difficulties in dispensing. Acerus made minor modifications to the manufacturing process that appear to have resolved the previously identified issues and has produced a new commercial batch of Natesto. On November 1, 2019, we announced that Health Canada classified the changes as level I, requiring the submission of a SNDS. Should Health Canada utilize the full regulatory allotted time for reviewing a SNDS, Acerus would expect the Revised Batch to be released in the Canadian Market in Q1-2021. In Q2-2019, we had previously impaired inventory by $0.3 million and accrued $0.5 million related to replacing products, discounts and potential returns due to the issue described above. However, due to the additional delays, the Company reversed the previous accruals related to discounts and replacement of product and has accrued $0.7 million for returns in the current quarter.
The following table indicates the revenue by product for the quarter (in US$000s):
Difference
$
$ 80
$ 172
$ (92)
(159)
364
(523)
(296)
-
(296)
(375)
536
(911)
203
883
(680)
5
164
(159)
$ (167)
$ 1,583
$ (1,750)
Gross margin declined by $0.8 million to negative $0.04 million compared to the prior year quarter. The current figure reflects the accrual for product returns described above and the reversal of the $0.4 million charge to cost of goods made in Q2-2019 when it was expected that the Company would replace the recalled NATESTO product.
Selling, general and administrative expenses (SG&A) increased to $3.2 million from $2.2 million in the prior year period. The current quarter reflects costs of $2.1 million in anticipation of the NATESTO United States A&R Agreement closing and subsequent launch. Absent this charge, SG&A expenses were $1.1 million or 50% lower than the comparable prior year period, reflecting decreased marketing and selling expenses related to NATESTO Canada and UriVarxTM and decreased salaries and benefits costs due to reductions in commercial headcount and reductions in bonus accrual. The Company will continue to review expenses and make adjustments where necessary in light of the recent recall and SNDS requirement. In particular, Acerus will be streamlining its future operating expenses to focus on the following key priorities: 1) the standing up of the US organization in anticipation of the go-live of the A&R Agreement, 2) the approval by Health Canada and launch of avanafil in the Canadian market, 3) supporting our global partners who are launching NATESTO in their respective markets and 4) strengthening the management of our third-party manufacturing network.
Research and development ("R&D") expense was $0.6 million for the current quarter, a slight decline from the $0.8 million for the prior year period.
Earnings before interest, tax, depreciation and amortization (EBITDA)1 was a loss of $3.7 million compared to an EBITDA loss of $1.6 million for the prior year quarter. Adjusted EBITDA1, was a loss of $3.4 million for the quarter compared to a loss of $1.5 million for the prior year period.
The Company incurred a net loss of $4.6 million or $(0.02) per share for the quarter compared to a loss of $2.9 million or $(0.01) per share for the third quarter of 2018.
Cash as of September 30, 2019 was $4.1 million compared with $3.8 million on December 31, 2018, reflecting the proceeds of a CDN$4.5 million private placement in Q1-2019, and a US$5.0 million subordinated debt facility entered into in Q3-2019 between the Company and First Generation Capital Inc., a company affiliated with the Chairman of the Board of Directors of the Company, offset by cash used in operations.
Summary of Results for the Nine Months Ended September 30, 2019 (compared to the Nine Months Ended September 30, 2018 unless otherwise noted)
NATESTO USA UPDATE
As indicated above, the Company and Aytu Bioscience jointly announced on July 30, 2019, that they had signed an amended and restated license agreement to allow Acerus to enter the US market directly and co-promote NATESTO to the specialist (urology and endocrinology) market. Under the terms of the new agreement, Aytu returns the NDA for NATESTO in the US back to Acerus. Going forward, Acerus will assume all regulatory and clinical responsibilities and costs for the product in the US Acerus will take on a more expansive role in matters such as US marketing, reimbursement and medical strategy as part of the companies joint commercialization committee. Aytu will retain its primary care sales force and will continue to book all product net revenue while serving as the exclusive US supplier of NATESTO to wholesalers, pharmacies and other customers that receive a direct shipment. Financial payments will be based upon a tiered level of net revenue, post cost of goods sold (COGS), based on annual sales performance in the respective Acerus and Aytu Sales Channels. This transaction is conditional on Acerus raising at least US$10 million in any combination of debt or equity by no later than January 29, 2020. In anticipation of the condition being satisfied, the Company has begun working with its partner, Syneos Health, to facilitate a launch by Acerus in early 2020.
Conference Call
Shareholders are reminded that the conference call to discuss the Companys results for the three- and nine-month period ending September 30, 2019 will be held on Thursday, November 14, 2019 at 8:30 a.m. Eastern Time. To access the call live, please dial 416-340-2219 or 1-800-478-9326. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.
A replay of the conference call will be available until 11:59 p.m. Eastern Time on Thursday, November 21, 2019 by dialing 905-694-9451 or 1-800-408-3053, using access code: 2401991#.
About AcerusAcerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of mens health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the US and other territories.
Acerus shares trade on TSX under the symbol ASP and on the OTCQB under the symbol ASPCF. For more information, visit http://www.aceruspharma.com and follow us on Twitter and LinkedIn.
1 Non-IFRS Financial Measures - EBITDA and Adjusted EBITDAThe non-IFRS measures included in this press release are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. When used, these measures are defined in such terms as to allow the reconciliation to the closest IFRS measure. These measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from our perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. Despite the importance of these measures to management in goal setting and performance measurement, we stress that these are non-IFRS measures that may have limits in their usefulness to investors.
We use non-IFRS measures, such as EBITDA and Adjusted EBITDA to provide investors with a supplemental measure of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS measures in the valuation of issuers. We also use non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets, and to assess our ability to meet our future debt service, capital expenditure and working capital requirements.
The definition and reconciliation of EBITDA and Adjusted EBITDA used and presented by the Company to the most directly comparable IFRS measures follows below:
EBITDA is defined as net (loss)/income adjusted for income tax, depreciation of property and equipment, amortization of intangible assets, interest on long-term debt and other financing costs, interest income, licensing revenue and changes in fair values of derivative financial instruments. Management uses EBITDA to assess the Companys operating performance.
Adjusted EBITDA is defined as EBITDA adjusted for, as applicable, royalty expenses associated with triggering events, milestones, share based compensation, impairment of intangible asset, foreign exchange (gain)/loss and the impact of charges related to a product recall. We use Adjusted EBITDA as a key metric in assessing our business performance when we compare results to budgets, forecasts and prior years. Management believes Adjusted EBITDA is an alternative measure of cash flow generation than, for example, cash flow from operations, particularly because it removes cash flow fluctuations caused by extraordinary changes in working capital. A reconciliation of net (loss)/income to EBITDA (and Adjusted EBITDA) is set out below.
2019
2018
2019
2018
$
(4,612
)
$
(2,871
)
$
(12,246
)
$
(13,735
)
-
2
-
2
177
447
642
1,300
64
Read more:
Acerus Reports Third Quarter and Year-to-Date Fiscal 2019 Financial Results - Business Wire
- How to inject Testosterone demonstrated by Dr Robert Carlson [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- How Not To Inject 200mg of Testosterone! [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- How to do a Testosterone Shot Injection [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Testosterone Injections: How To Inject Testosterone [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- How to Inject Testosterone Safely [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Male testosterone dropping more rapidly - UpperMichigansSource.com [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Springfield weighted down with testosterone. Where are the women? - Chicago Sun-Times [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- What is Testosterone? - Live Science: The Most Interesting ... [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Study: Women with more naturally occurring testosterone have competitive advantage - ESPN [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Dear Dr. Roach: Testosterone treatment reserved for men with symptoms - Herald & Review [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Low Testosterone - WebMD: Symptoms, Health Effects, and ... [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Testosterone - WebMD [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Column: Testosterone treatment reserved for men with symptoms ... - Prescott Daily Courier [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- Testosterone treatment reserved for men with symptoms | To Your ... - STLtoday.com [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- Merkel's Patient Diplomacy Is Tested by Trump and Putin's 'Axis of Testosterone' - Wall Street Journal (subscription) [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- Trump and Putin Meet in Testosterone-Fueled Face-Off - New York Times [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- 7 Testosterone-Boosting Foods - Mercola.com [Last Updated On: July 9th, 2017] [Originally Added On: July 9th, 2017]
- How to Deal with Testosterone Decline - Mercola.com [Last Updated On: July 9th, 2017] [Originally Added On: July 9th, 2017]
- Cialis daily testosterone - Cialis daily cost canada - Van Wert independent [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- Canadian pharmacy nolvadex - Nolvadex during testosterone cycle - Van Wert independent [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- Testosterone and propecia - Propecia pictures before and after - Van Wert independent [Last Updated On: July 11th, 2017] [Originally Added On: July 11th, 2017]
- The link between baldness, testosterone and prostate cancer | www ... - Western Queens Gazette [Last Updated On: July 12th, 2017] [Originally Added On: July 12th, 2017]
- Should Testosterone Be Regulated in Female Athletes? - NOVA Next [Last Updated On: August 1st, 2017] [Originally Added On: August 1st, 2017]
- Wayne Allyn Root Is Thrilled That 'Real Men With Testosterone' Are Running The White House - Right Wing Watch [Last Updated On: August 1st, 2017] [Originally Added On: August 1st, 2017]
- Testosterone: The Test | Testosterone Test: Total ... [Last Updated On: August 3rd, 2017] [Originally Added On: August 3rd, 2017]
- 6 Ways to Increase Testosterone Levels Naturally - wikiHow [Last Updated On: August 3rd, 2017] [Originally Added On: August 3rd, 2017]
- What Qualifies a Woman to Compete as a Woman? The Ugly Fight Is Here Again - New York Times [Last Updated On: August 4th, 2017] [Originally Added On: August 4th, 2017]
- Testosterone - Steroid .com [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- Doctors Address Low Testosterone Ads - CBS St. Louis [Last Updated On: August 8th, 2017] [Originally Added On: August 8th, 2017]
- Track authorities move to again bar women with naturally high testosterone from competing - STAT [Last Updated On: August 8th, 2017] [Originally Added On: August 8th, 2017]
- Caster Semenya refuses to be distracted at London 2017 by testosterone debate - Evening Standard [Last Updated On: August 8th, 2017] [Originally Added On: August 8th, 2017]
- Phenibut high - Nolvadex raise testosterone levels - Bournville Village [Last Updated On: August 8th, 2017] [Originally Added On: August 8th, 2017]
- Does testosterone optimization cause prostate cancer? - Meridian Star [Last Updated On: August 12th, 2017] [Originally Added On: August 12th, 2017]
- 'Intersex' athletes to learn if they will be forced to take drugs to ... - Telegraph.co.uk [Last Updated On: August 12th, 2017] [Originally Added On: August 12th, 2017]
- Caster Semenya shrugs off 'nonsense' over gender tests and testosterone levels - Express.co.uk [Last Updated On: August 14th, 2017] [Originally Added On: August 14th, 2017]
- Testosterone and sexual function. - UroToday - UroToday [Last Updated On: August 14th, 2017] [Originally Added On: August 14th, 2017]
- Lipocine Announces FDA Acknowledgement of TLANDO (LPCN 1021) NDA Resubmission; PDUFA Goal Date ... - GlobeNewswire (press release) [Last Updated On: August 14th, 2017] [Originally Added On: August 14th, 2017]
- Fmr. Air Force Secretary: Trump Needs to 'Tone Back the Testosterone' - Mediaite [Last Updated On: August 14th, 2017] [Originally Added On: August 14th, 2017]
- How testosterone regulates singing in canaries - Phys.Org [Last Updated On: August 16th, 2017] [Originally Added On: August 16th, 2017]
- The Testosterone-Fueled Presidency - Common Dreams [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- Testosterone therapy improves sexual functions - India New England [Last Updated On: August 17th, 2017] [Originally Added On: August 17th, 2017]
- Elevated testosterone causes bull market trading - Medical Xpress - Medical Xpress [Last Updated On: August 18th, 2017] [Originally Added On: August 18th, 2017]
- Older men with 'low T' can improve their sex lives with testosterone therapy, study says - Men's Fitness [Last Updated On: August 18th, 2017] [Originally Added On: August 18th, 2017]
- Testosterone makes men more impulsive - The Economist [Last Updated On: August 18th, 2017] [Originally Added On: August 18th, 2017]
- Elevated testosterone linked to 'reckless' financial trading, study ... - CBC.ca [Last Updated On: August 20th, 2017] [Originally Added On: August 20th, 2017]
- Testosterone - New World Encyclopedia [Last Updated On: August 20th, 2017] [Originally Added On: August 20th, 2017]
- testosterone | hormone | Britannica.com [Last Updated On: August 20th, 2017] [Originally Added On: August 20th, 2017]
- Testosterone Supplements | Walgreens [Last Updated On: August 20th, 2017] [Originally Added On: August 20th, 2017]
- Delayed Ejaculation and Associated Complaints: Relationship to Ejaculation Times and Serum Testosterone Levels. - UroToday [Last Updated On: August 21st, 2017] [Originally Added On: August 21st, 2017]
- Side effects of brain radiation for small cell lung cancer - Testosterone enanthate and nandrolone decanoate cycle - Filipino Express [Last Updated On: August 21st, 2017] [Originally Added On: August 21st, 2017]
- T-Nation - Strength Training, Bodybuilding & Online ... [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Testosterone Replacement Therapy - Testosterone Treatment [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Blood Test Predicts Prostate Tumor Resistance - Technology Networks [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Androgen (testosterone) deficiency | Andrology Australia [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- How to Boost Free Testosterone - Nugenix [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- 10 Signs of Low Testosterone in Women | ActiveBeat [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- testosterone | eBay [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- TTFB - Clinical: Testosterone, Total, Bioavailable, and Free ... [Last Updated On: August 24th, 2017] [Originally Added On: August 24th, 2017]
- Now we men can blame our hormones: testosterone is trouble - The Guardian [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
- Testosterone replacement can affect sex drive, osteoporosis | To ... - STLtoday.com [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
- Elevated Testosterone Linked to 'Reckless' Financial Trading, Study Finds - Traders Magazine [Last Updated On: August 27th, 2017] [Originally Added On: August 27th, 2017]
- Dr. Roach: Testosterone replacement can affect sex drive, osteoporosis - LubbockOnline.com [Last Updated On: August 27th, 2017] [Originally Added On: August 27th, 2017]
- Testosterone Replacement Therapy Market Global Insights and ... - E News Access (press release) [Last Updated On: September 1st, 2017] [Originally Added On: September 1st, 2017]
- Testosterone pct nolvadex - Proviron and nolvadex for pct - Forward Florida [Last Updated On: September 1st, 2017] [Originally Added On: September 1st, 2017]
- Testosterone replacement therapy associated with improved urinary, sexual function - ProHealth [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Viagra testosterone mail order - Viagra prescription cost 2016 - Magnetic Media (press release) [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Testosterone | You and Your Hormones from the Society for ... [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Does propecia work in owmen - How long before propecia works - Testosterone replacement therapy and propecia - Twin Cities Arts Reader [Last Updated On: September 5th, 2017] [Originally Added On: September 5th, 2017]
- Testosterone Lawsuits Begin, Outcomes Split - LawyersandSettlements.com [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- How short-term increases in testosterone change men's thinking style - The British Psychological Society [Last Updated On: September 7th, 2017] [Originally Added On: September 7th, 2017]
- Testosterone(androgen) - WebMD [Last Updated On: September 23rd, 2017] [Originally Added On: September 23rd, 2017]
- How Long Does Testosterone (TRT) Take To Work? [Last Updated On: September 28th, 2017] [Originally Added On: September 28th, 2017]
- Testosterone Deficiency, Erectile Dysfunction, and ... [Last Updated On: October 1st, 2017] [Originally Added On: October 1st, 2017]
- Testim VS Androgel - Testosterone Replacement Therapy [Last Updated On: October 19th, 2017] [Originally Added On: October 19th, 2017]
- Testosterone - webmd.com [Last Updated On: November 10th, 2017] [Originally Added On: November 10th, 2017]
- Testosterone | Hormone Health Network [Last Updated On: November 17th, 2017] [Originally Added On: November 17th, 2017]
- VTrex - Testosterone Boosting Male Enhancement | Free Sample [Last Updated On: December 17th, 2017] [Originally Added On: December 17th, 2017]
- Testosterone : The Test | Testosterone Test - labtestsonline.org [Last Updated On: December 29th, 2017] [Originally Added On: December 29th, 2017]
- Testosterone - Lab Tests Online [Last Updated On: December 31st, 2017] [Originally Added On: December 31st, 2017]
- Aggression - Wikipedia [Last Updated On: February 4th, 2018] [Originally Added On: February 4th, 2018]